Close Menu

InDevR

The in vitro diagnostic is designed to detect whole gene segments for influenza A and B viruses and can characterize viruses as seasonal or nonseasonal.

The certification comes ahead of the company's planned launch of a microarray-based test for differentiating seasonal and non-seasonal influenza viruses.

St. Jude's Richard Webby will assess the performance of InDevR's FluChip-8G test on non-seasonal influenza viruses.

Agilent Technologies this week announced updates to its SurePrint miRNA Microarrays to include targets from the latest version of the miRBase public miRNA database.

NEW YORK (GenomeWeb) — Researchers at Johns Hopkins University have performed the first validation of the Cepheid Xpert Flu assay in a population of emergency room patients with acute undifferentiated respiratory illness.

NEW YORK (GenomeWeb) – By the end of 2016, InDevr aims to have a microarray-based clinical test on the market for genotyping influenza viruses.

NEW YORK (GenomeWeb) – InDevr announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority to finish the development of a microarray-based test for influenza.

Applied Microarrays and InDevR this week announced a new partnership that will pair AMI's contract array manufacturing resources with InDevR's instrumentation and assay development capabilities.

NEW YORK (GenomeWeb) – InDevR and Applied Microarrays said today that they will work together to offer custom microarrays, instruments, and reagents for multiplexed assays.

Pages

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.